Galecto (GLTO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
16 Dec, 2025Executive summary
Special Meeting will vote on six key proposals, including share issuance, charter amendment, redomestication, new equity plans, and meeting adjournment.
Board recommends voting in favor of all proposals, citing strategic benefits and alignment with shareholder interests.
The meeting will be held virtually, and only shareholders of record as of the set date may vote.
Voting matters and shareholder proposals
Proposal 1: Approve issuance of common stock upon conversion of Series B and C Preferred Stock.
Proposal 2: Amend Certificate of Incorporation to increase authorized common shares from 300M to 500M.
Proposal 3: Redomesticate from Delaware to Cayman Islands, adopting new governing documents.
Proposal 4: Approve 2026 Equity Incentive Plan, authorizing 9,299,832 shares with annual increases.
Proposal 5: Approve 2026 Employee Stock Purchase Plan, authorizing 619,989 shares with annual increases.
Proposal 6: Approve adjournment/postponement of the meeting if more votes are needed.
Board of directors and corporate governance
Board remains unchanged post-redomestication, with current directors and officers continuing in their roles.
Board structure includes staggered three-year terms and classified board provisions.
Anti-takeover provisions include classified board, special meeting limitations, and preferred stock rights.
Latest events from Galecto
- Cash position of $535M supports pipeline progress; net loss driven by R&D acquisition costs.GLTO
Q4 202520 Mar 2026 - Damora advances potent CALR-targeted therapies for ET and MF, aiming for broad clinical impact.GLTO
Leerink Global Healthcare Conference 20269 Mar 2026 - Key proposals include stock conversion, capital increase, redomestication, and new equity plans.GLTO
Proxy Filing31 Dec 2025 - BRM-1420, a dual ENL-YEATS/FLT3 inhibitor, advances toward clinical trials for high-risk AML.GLTO
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202524 Dec 2025 - Advancing preclinical antibody and small molecule therapies for blood cancers after major PIPE raise.GLTO
Registration Filing16 Dec 2025 - Annual meeting to vote on director elections, stock issuance, and auditor ratification.GLTO
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, stock conversion, auditor, and review governance and compensation.GLTO
Proxy Filing2 Dec 2025 - Key votes include director elections, stock issuance approval, and auditor ratification.GLTO
Proxy Filing2 Dec 2025 - Acquisition expands blood cancer pipeline and secures $285M funding for clinical milestones through 2029.GLTO
M&A Announcement17 Nov 2025